New York, NY – FastX today announces the official launch of its platform, a next-generation exchange built for professional and active traders who require institutional‑grade tools without surrendering custody or control of their assets. FastX goes live globally on 5 May, with traders able to access the platform directly at fastx.co.

FastX combines deep on‑chain liquidity, multi‑asset perpetual futures markets, and an advanced copy-trading engine designed to bridge the gap between traditional finance and the decentralized digital asset ecosystem. By leveraging blockchain technology, the platform delivers low‑latency mirroring of trades across major decentralized networks worldwide—while keeping users in full control of their own wallets and risk.

“FastX was created by traders for traders,” said Adelene, Chief Executive Officer of FastX. “We’ve spent our careers on Wall Street desks and in crypto markets, and we’ve seen the same problems repeat: opaque execution, misaligned incentives, and copytrading systems that ask users to blindly outsource decisions. FastX is our answer—a decentralised, transparent infrastructure layer where traders keep custody, and technology works to augment, not replace, their edge.”

Backed by a team of veteran traders with more than 50 years of combined experience across top Wall Street institutions and leading crypto trading firms, FastX is built from the ground up as a decentralised protocol. Users connect their own wallets, maintain self‑custody at all times, and interact with smart contracts that execute trades on‑chain, rather than relying on a centralised broker or custodial exchange.

At launch, FastX will offer:

• Deep, on‑chain liquidity across a wide range of perpetual markets, designed to support serious position sizes with tight spreads and minimal slippage.
• A fast, intuitive trading interface accessible directly via fastx.co, allowing traders to plug in with their preferred wallet and start trading in minutes.
• A transparent affiliate and points system that shares a meaningful portion of platform fees with the community and rewards traders and partners who help grow liquidity and volume.

The flagship feature of FastX is its next‑generation copytrading system. Unlike traditional social trading products that mirror orders on a single venue with unpredictable delays, FastX’s engine is designed to route and synchronise copy trades across major decentralised exchanges, layering those capabilities on top of FastX’s own liquidity.

The result is a copytrading experience that aims to:

• Minimise latency between lead and follower execution.
• Mitigate structural risks such as slippage, desync, and obvious forms of manipulation.
• Exploit decentralised advantages, such as transparent on‑chain track records and programmable risk controls, without turning the platform into a centralised black box.

“Copytrading has always been typecast as a blind, autonomous disaster waiting to happen,” Adelene added. “FastX takes the opposite stance. We use technology to bring more transparency, not less—on‑chain track records, built‑in risk parameters, and infrastructure that reduces front‑running and execution games wherever possible. Over time, our goal is to layer AI‑driven intelligence on top of this foundation so that users can benefit from advanced analytics and risk management, rather than just ‘follow and hope’.”

FastX is currently seed‑funded by a network of angels deeply embedded in the global crypto trading ecosystem. These backers share a common view that the next generation of markets will be built on open, verifiable rails and that traders deserve better, more transparent instrumentation for expressing and managing risk. FastX is assembling a strong advisory board of experienced traders, market makers, and technologists to guide the exchange through its next phase of growth.

As a decentralised protocol, FastX does not take custody of user funds and does not operate as a traditional broker. All positions, liquidations, and fee flows are visible on‑chain, giving traders clear, verifiable insight into how the system behaves under all market conditions.

“Our vision is simple,” said Adelene. “We want professional‑grade perpetuals and intelligent copytrading to live where they belong: on transparent, decentralised infrastructure, not in a black box. Launching FastX on 5 May is the first step. From here, we’ll continue to ship faster execution, smarter tooling, and AI‑enhanced copytrading that helps traders survive and thrive in 24/7 markets.”

Traders can learn more and access the exchange at https://fastx.co.

About FastX

FastX focuses on building decentralised financial infrastructure and tools for professional traders and sophisticated market participants. The company backs products that prioritise self‑custody, transparency, and robust risk management in rapidly evolving digital asset markets.

Media Contact

Brand: FastX Perpetuals Exchange

Email: support@fastx.co

Contact: Ella Huang

Website: https://fastx.co/

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.

The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology (ENT). It also marks another significant milestone in the Group’s research and development progress in the field of type 2 inflammatory diseases. If the Product is successfully approved for marketing, the Group will leverage its strong academic promotion capabilities and extensive commercialization network to accelerate the commercialization of the Product. It is also expected to further enhance the academic brand influence of CMS Vision in the relevant specialty areas and provide new momentum for the Group’s business growth.

BIC Potential: Dosing once every 4 weeks; Phase III study met the primary endpoint with a favorable safety profile

MG-K10 is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling pathways of the key type 2 inflammatory cytokines IL-4 and IL-13, thereby exerting immunomodulatory effects. It is being developed for the treatment of type 2 inflammatory diseases, including seasonal allergic rhinitis, asthma, atopic dermatitis (AD), prurigo nodularis, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Currently marketed anti-IL-4Rα therapies require administration once every two weeks. MG-K10, with its longer half-life, enabling a once-every-four-weeks dosing regimen. It therefore has the potential to become the first long-acting anti-IL-4Rα monoclonal antibody to be marketed globally, with the potential to be best-in-class. MG-K10 has met the primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in adult patients with moderate-to-severe seasonal allergic rhinitis. The results of the Phase III study demonstrated that the primary endpoint achieved statistical significance, with significantly superior efficacy compared with the placebo group, and a favorable safety profile.

Focusing on Unmet Needs: ~250 million patients; 62% of moderate-to-severe patients remain inadequately controlled; long-acting breakthrough brings new treatment opportunities

Allergic rhinitis is a chronic inflammatory disease of the nasal mucosa mediated by IgE, with type 2 inflammation as the core pathogenic mechanism. It occurs in susceptible individuals upon exposure to environmental allergens such as pollen and dust mites. In recent years, the prevalence of the disease in China has increased from 11.1% to 17.6%, affecting approximately 250 million people[1], among whom 52.2% are patients with persistent moderate-to-severe disease[2]. The disease burden is significant and has become an important public health issue. Current standard treatments, including intranasal corticosteroids and antihistamines, have notable limitations. 62% of patients with moderate-to-severe disease remain inadequately controlled[3]. Long-term use of intranasal corticosteroids may lead to adverse reactions such as epistaxis[4], while antihistamines are often associated with side effects such as drowsiness[5], indicating significant unmet clinical needs. As a biologic therapy targeting IL-4Rα, MG-K10 can block the type 2 inflammatory pathway at its source. Compared with currently approved biologics targeting the same pathway (which require dosing once every two weeks), MG-K10 achieves a differentiated breakthrough in dosing frequency with its long-acting property allowing administration once every four weeks, thereby significantly extending dosing intervals. This may help improve patient treatment adherence and reduce the time and economic burden associated with frequent hospital visits. The Product has the potential to provide a new treatment option for patients with moderate-to-severe disease who respond poorly to conventional therapies, thereby reducing the individual and socio-economic burden associated with the disease.

On 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiary for MG-K10. In accordance with the Agreement and supplementary agreements, the Group has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon Holdings Limited has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China.

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

Reference

1. Cheng L, Chen J, Fu Q, et al. Chinese Society of Allergy Guidelines for Diagnosis and Treatment of Allergic Rhinitis. Allergy Asthma Immunol Res. 2018;10:300‑353.
2. Zheng, Ming et al. “Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China.” Allergy vol. 76,2 (2021): 577-581. doi:10.1111/all.14561
3. White, P et al. “Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?” Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology vol. 28,3 (1998): 266-70. doi:10.1046/j.1365-2222.1998.00237.x
4. Rosenblut, A et al. “Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis.” Allergy vol. 62,9 (2007): 1071-7. doi:10.1111/j.1398-9995.2007.01521.x
5. Bernstein, Jonathan A et al. “Allergic Rhinitis: A Review.” JAMA vol. 331,10 (2024): 866-877. doi:10.1001/jama.2024.0530

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations 

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/